12:01 :
MediciNova dives on asthma study results -
BOSTON (MarketWatch) -- Shares of MediciNova Inc. dove 46% to $1.50 Thursday, the day after it reported that a Phase II clinical study for its drug MN-221 failed to show it was effective in treating certain symptoms of acute asthma attacks. ...